Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today the presentation of preclinical data demonstrating that topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi), which has been formulated utilizing Kala’s proprietary mucosal-penetrating particle (MPP) technology, greatly enhanced drug levels in the retina. These data, which were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting, demonstrated that by utilizing its MPP technology Kala could create potential non-invasive treatments for retinal diseases such as wet age-related macular degeneration (wet AMD).
Help employers find you! Check out all the jobs and post your resume.
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today the presentation of preclinical data demonstrating that topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi), which has been formulated utilizing Kala’s proprietary mucosal-penetrating particle (MPP) technology, greatly enhanced drug levels in the retina. These data, which were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting, demonstrated that by utilizing its MPP technology Kala could create potential non-invasive treatments for retinal diseases such as wet age-related macular degeneration (wet AMD).
Help employers find you! Check out all the jobs and post your resume.
